Saturday 17 October 2026 Export POCI’s income statement to Excel — free account

Precision Optics Corp.

POCI Healthcare Medical Instruments & Supplies

Precision Optics Corp.’s revenue for fiscal 2026 (year ended June 2026) was $31.5 million, up 65.2% from fiscal 2025. In the quarter to June 2026, revenue grew 42.0%, EPS grew 117.4%, free cash flow fell 45.6% and total debt fell 31.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.26 0.09 −2.07%

Follow POCI

Alert me

Market cap: $47.7M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 5/9
Altman Z: 0.59
Beneish M: −2.28
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.23

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	3	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 6.93%

Capital & Financial Ratios $m

Market Cap 47.73

Revenue 31.53

Net Income (3.63)

Free Cash Flow (1.98)

Net Debt (8.55)

Current Ratio 2.28

Debt/Equity 0.06

P/E ratio 0.00

Fwd P/E —

P/S ratio 1.15

P/B ratio 1.79

Past 5Y EPS Growth —

This Y EPS Growth 30.23%

Next Y EPS Growth 110.00%

Next Y revenue growth (0.16%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 11.39%

10-year low 10-year high

P/B against its own 10 years 1.73%

10-year low 10-year high

EV/Sales against its own 10 years 5.05%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	3	0	2	10
Receivables	4	4	4	6
Inventory	3	3	4	4
Other	—	—	—	—
	10	7	10	20

	2023	2024	2025	2026
Payables	2	1	3	4
ST’ Debt	1	1	1	1
Other	1	1	2	2
	5	5	6	9

Compound Annual Growth %

	10y	5y	3y
Sales	23.19%	24.19%	14.43%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	42.55%	42.77%	19.10%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	7	7	9	9	32
’25	4	5	4	6	19
’24	4	5	5	5	19
’23	5	6	5	5	21
’22	2	4	5	5	16
’21	3	3	2	3	11

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	0	0	(1)	(1)	(2)
’25	0	(1)	(2)	0	(3)
’24	(1)	0	0	(1)	(3)
’23	0	0	1	(1)	0
’22	0	(1)	0	0	(1)
’21	0	0	0	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	0	0	(1)	(1)	(2)
’25	0	(1)	(2)	(1)	(4)
’24	(1)	0	0	(1)	(3)
’23	0	0	0	(1)	0
’22	0	(1)	0	0	(1)
’21	0	0	0	0	0

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(0.21)	(0.23)	(0.01)	0.03	(0.43)
’25	(0.21)	(0.15)	(0.30)	(0.18)	(0.85)
’24	(0.08)	(0.13)	(0.05)	(0.23)	(0.49)
’23	(0.03)	0.09	(0.07)	(0.02)	(0.03)
’22	(0.04)	(0.09)	(0.02)	0.06	(0.18)
’21	0.00	(0.06)	0.12	(0.09)	(0.02)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	1.20	1.23	3.15	1.65	4.35	1.95	5.45	3.47	3.77	3.55	Analyst estimates 2027–2029 Powerpack
	High	1.95	5.55	6.12	6.75	9.00	7.85	7.20	6.90	5.34	6.15
People
People	Employees	27	30	62	60	52	77	85	84	90	108
	Revenue/emp, $m	0.12	0.13	0.11	0.17	0.21	0.20	0.25	0.23	0.21	0.29
Income, $m
Income, $m	Revenue	3	4	7	10	11	16	21	19	19	32
	Gross margin, %	24.53	36.70	31.19	33.89	32.17	31.43	36.75	30.35	17.83	17.22
	EBT	(1)	0	(1)	(1)	0	(1)	0	(3)	(6)	(4)
	EBT margin, %	(31.88)	(8.68)	(9.02)	(14.35)	(0.95)	(5.92)	(0.68)	(15.44)	(30.27)	(11.50)
	Net income	(1)	0	(1)	(1)	0	(1)	0	(3)	(6)	(4)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	1.13	1.23	1.78	2.29	2.41	3.00	3.71	3.15	2.81	3.70
	Earnings	(0.36)	(0.12)	(0.15)	(0.33)	(0.02)	(0.18)	(0.03)	(0.49)	(0.85)	(0.43)
	Cash flow	(0.24)	0.03	(0.27)	(0.14)	0.01	(0.18)	(0.01)	(0.44)	(0.50)	(0.18)
	Capex	(0.01)	(0.01)	(0.04)	(0.04)	(0.03)	(0.03)	(0.01)	(0.05)	(0.03)	(0.05)
	Free cash flow	(0.25)	0.02	(0.31)	(0.17)	(0.02)	(0.21)	(0.02)	(0.49)	(0.53)	(0.23)
	Book value	0.20	0.17	0.88	0.64	0.78	1.72	2.13	1.66	1.81	2.39
	Shares, m	3	3	4	4	4	5	6	6	7	9
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	1.59	1.29	1.92	1.90	2.09	1.99	1.66	1.98	1.74	1.38
	P/B	8.96	9.23	3.88	6.80	6.50	3.48	2.89	3.75	2.71	2.14
	EV/Sales	1.56	1.19	1.59	1.79	2.02	2.11	1.65	2.13	1.75	1.11
	EV/FCF	(7.01)	88.10	(9.17)	(23.58)	(284.97)	(30.44)	(259.56)	(13.64)	(9.19)	(17.66)
Cash, $m
Cash, $m	Operating cash flow	(1)	0	(1)	(1)	0	(1)	0	(3)	(3)	(2)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(1)	0	(1)	(1)	0	(1)	0	(3)	(4)	(2)
Balance, $m
Balance, $m	Working capital	0	0	3	2	2	2	5	2	4	11
	Total debt	0	0	0	1	0	2	3	3	2	1
	Net debt	0	0	(2)	0	(1)	2	0	3	0	(9)
	Shareholders’ equity	1	1	3	3	3	9	12	10	12	20
Returns, %
Returns, %	ROA	(51.30)	(16.30)	(12.29)	(20.60)	(1.63)	(8.09)	(0.79)	(16.10)	(31.50)	(13.93)
	ROIC	(135.14)	(123.86)	(34.70)	(34.33)	(20.06)	(8.76)	(3.36)	(13.23)	(28.09)	(18.59)
	ROE	(175.72)	(62.62)	(31.21)	(46.39)	(3.31)	(14.97)	(1.38)	(26.69)	(51.78)	(22.26)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026 · fundamentals updated 30 Sep 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NYXH Nyxoah SA	$121.2M	— (loss-making)	— (loss-making)	+486.62% (above 0%: growing)	n/m	+4.01% (above 0%: growing)	59.73%	(268.25%)	Compare
STXS Stereotaxis Inc.	$105.2M	— (loss-making)	— (loss-making)	−12.82% (below 0%: shrinking)	n/m	+0.45% (above 0%: growing)	58.49%	(59.56%)	Compare
MBOT Microbot Medical Inc.	$63.8M	— (loss-making)	—	+1,047.62% (above 0%: growing)	n/m	−98.72% (below 0%: shrinking)	(266.80%)	(2,567.63%)	Compare
ZTEKF Zentek Ltd.	$62.3M	— (loss-making)	—	−95.36% (below 0%: shrinking)	n/m	−254.61% (below 0%: shrinking)	0.00%	0.00%	Compare
DXR Daxor Corporation	$59.6M	4.7×	7.6×	−27.62% (below 0%: shrinking)	n/m	−88.56% (below 0%: shrinking)	0.00%	0.00%	Compare
POCI Precision Optics Corp.	$47.7M	— (loss-making)	—	+41.95% (above 0%: growing)	n/m	−45.64% (below 0%: shrinking)	25.34%	(1.21%)
NEPH Nephros Inc.	$38.1M	23.4×	76.0×	+36.16% (above 0%: growing)	+450.00% (above 0%: growing)	−31.49% (below 0%: shrinking)	66.91%	20.16%	Compare
HBIO Harvard Bioscience, Inc.	$37.8M	— (loss-making)	— (loss-making)	+11.13% (above 0%: growing)	n/m	−123.43% (below 0%: shrinking)	55.57%	(4.30%)	Compare
MLSS Milestone Scientific, Inc.	$29.6M	— (loss-making)	— (loss-making)	+22.27% (above 0%: growing)	n/m	+66.68% (above 0%: growing)	67.24%	(37.37%)	Compare
Median of peers	$60.9M	—	—	+16.70%	—	−60.03%	57.03%	(20.83%)

All 55 Medical Instruments & Supplies stocks →

Precision Optics Corp. (POCI) key facts

Strength: Precision Optics Corp.’s revenue for fiscal 2026 (year ended June 2026) was $31.5 million, up 65.2% from fiscal 2025.
Precision Optics Corp. (POCI) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, POCI traded at $4.26, a market capitalization of $47.7 million.
Return on equity was −22.3% and debt-to-equity 0.06.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 0.59 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 30, 2026.